Valion Bio, Inc.
corporate_fare Company Profile
Valion Bio, Inc. (NASDAQ:VBIO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 33 items for VBIO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for VBIO spans 8-K, S-3, DEF 14A, PRE 14A.
Recent high-impact activity:
- Valion Bio Stockholders Grant Board 1-for-2 to 1-for-12 Reverse Split Authority
- Valion Bio Loses President, COO and CFO Lisa Wolf in Single Resignation
- Valion Bio Fires General Counsel; Entolimod Advances to Fully Funded AFRRI Efficacy Study
- NIAID Advances Entolimod Into Fully Funded GI-ARS Efficacy Study; December Data Readout
- Valion Bio Reports Clean Entolimod Safety Data, Advancing to Fully Funded AFRRI Efficacy Study
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 230,766 shares in VBIO as of the October 30, 2026 settlement, a 99.8% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 43.2% of VBIO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for VBIO, detected from its recent SEC filings · based on capital-structure filings through 2026-10-08.
$100M Shelf Registration Filed · $5M ATM Program with Rodman & Renshaw
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →